Drugs / ARRY-371797
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00790049 | Oct 2008 → Jan 2009 | — | Array BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT00729209 | Jul 2008 → Apr 2009 | rheumatoid arthritis | Array BioPharma | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT02351856 | Feb 2015 → Dec 2020 | dilated cardiomyopathy 1A | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02057341 | Feb 2014 → May 2016 | dilated cardiomyopathy 1A | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01366014 | Jun 2011 → Jun 2012 | osteoarthritis, knee | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00811499 | Dec 2008 → Sep 2009 | ankylosing spondylitis | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00663767 | Apr → Jun 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00542035 | Nov 2007 → Feb 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03439514 | Apr 2018 → Oct 2022 | dilated cardiomyopathy, laminopathy | Pfizer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARRY-371797 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00663767 ↗ |
| Known as | PF-07265803 | “In a phase 2 trial and long-term extension, the selective p38α MAPK (mitogen-activated protein kinase) inhibitor, ARRY-371797 (PF-07265803), was associated with an improved...” PMID 38979608 ↗ Jul 20242“ARRY-371797 (PF-07265803), a potent, selective, oral, small-molecule inhibitor of the p38α mitogen-activated protein kinase pathway” PMID 36114020 ↗ Sep 2022 “ARRY-371797 (PF-07265803)” NCT03439514 ↗ |
| Action | Inhibit | “ARRY-371797, p38 inhibitor; oral” NCT00542035 ↗ |
| Modality | Small molecule | “small-molecule inhibitor of the p38α mitogen-activated protein kinase pathway” PMID 36114020 ↗ Sep 2022 |
| Route | Oral | “ARRY-371797, p38 inhibitor; oral” NCT00542035 ↗ |